{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-197129","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.814087+00:00","generated_at":"2026-05-15T00:29:59.285649+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cerus Q1 revenue up 23% to $59.9M, raises FY product revenue guidance","bullets":["Product revenue $53.7M (+24% YoY); total revenue $59.9M (+23% YoY).","Net loss improved to $1.6M ($0.01/sh) from $7.7M ($0.04/sh) a year ago; Non-GAAP adjusted EBITDA $4.0M vs $0.2M.","Raises full-year 2026 product revenue guidance to $227M-$231M (was $224M-$228M); IFC revenue guided $22M-$24M.","Signed 4-year supply agreement with Établissement Français du Sang (EFS) for INTERCEPT Blood System and INT200.","CEO transition: COO Vivek Jayaraman to become CEO effective July 1, 2026; current CEO William Greenman to become executive chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-197129","json":"https://secwatch.observer/filing/0001193125-26-197129.json","markdown":"https://secwatch.observer/filing/0001193125-26-197129.md","text":"https://secwatch.observer/filing/0001193125-26-197129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000119312526197129/0001193125-26-197129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000119312526197129/cers-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:29:59.285649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46fb8aa09ed5b976353cd4e4015ff46de0aa53e8","claim":"CERUS CORP reported first quarter ended March 31, 2026 results: revenue $59.9 million, net income $1.6 million, or $0.01 per basic and diluted share. Guidance raised.","evidence_excerpt":"reference in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Cerus Corporation Announces First Quarter 2026 Financial Results First Quarter 2026 Total Revenue of $59.9 million, Up 23% Over Prior Year; First Quarter 2026 Product Revenue of $53.7 million, Up 24% Over Prior Year Raising Full Year Product Revenue Guidance Range to $227 million - $231","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1020214/000119312526197129/0001193125-26-197129-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$59.9 million"},{"label":"Net income","value":"$1.6 million, or $0.01 per basic and diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}